Correlation of progression-free and post-progression survival with overall survival in advanced colorectal cancer
-
Published:2013-01
Issue:1
Volume:24
Page:186-192
-
ISSN:0923-7534
-
Container-title:Annals of Oncology
-
language:en
-
Short-container-title:Annals of Oncology
Author:
Petrelli F.,Barni S.
Subject
Oncology,Hematology
Reference60 articles.
1. Cetuximab plus irinotecan, fluorouracil, and leucovorin as first-line treatment for metastatic colorectal cancer: updated analysis of overall survival according to tumor KRAS and BRAF mutation status;Van Cutsem;J Clin Oncol,2011
2. Cancer treatment and survivorship statistics, 2012;Siegel;CA Cancer J Clin,2012
3. Incremental cost-effectiveness of the pre- and post-bevacizumab eras of metastatic colorectal cancer therapy in British Columbia, Canada;Hedden;Eur J Cancer,2012
4. Survival of patients with advanced colorectal cancer improves with the availability of fluorouracil-leucovorin, irinotecan, and oxaliplatin in the course of treatment;Grothey;J Clin Oncol,2004
5. Surrogate end points for median overall survival in metastatic colorectal cancer: literature-based analysis from 39 randomized controlled trials of first-line chemotherapy;Tang;J Clin Oncol,2007
Cited by
64 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献